Statista. In June 2022, we transferred our commercial operations in the Russian Federation to a third-party distributor and incurred $38 million of exit costs through September 30, 2022 . By using our services, you agree to our use of cookies. Chart. View Bristol-Myers Squibb Company's Owner Earnings Yield trends, charts, and more. Bristol Myers Squibb posted first quarter revenues of $11.1 billion, an increase of 3%, or 1% when adjusted for foreign exchange. Please check your download folder. It has also divested 13 assets. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. BRISTOL MYERS SQUIBB CO 10-K (Annual Reports) 2009-02-20 - Free ebook download as PDF File (.pdf), Text File (.txt) or read book online for free. Get the tools used by (smart) 2 investors. Please create an employee account to be able to mark statistics as favorites. In November, the company announced that the Phase 3 CheckMate -816 trial met the co-primary endpoint of improved event-free survival (EFS) in patients with resectable Stage IB to IIIA non-small cell lung cancer. This information is among the primary indicators that we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. 58% and 54% of total pharmaceutical net sales in 2008, 2007 and 2006, respectively, . Get comparison charts for value investors! Total Assets 109,314,000 118,481,000 129,944,000 34,986,000 Total Liabilities Net Minority Interest 73,308,000 80,599,000 78,246,000 20,859,000 Total Equity Gross Minority Interest. 02/04/2022. 10-K (reporting date: 2020-12-31), Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie. Bristol-Myers Squibb Company revised earnings guidance for the year 2022. Investors and the general public are invited to listen to a . Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95. There will be a conference call on February 4, 2022 at 8 a.m. The final column . At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. Discover the latest ERP, HCM, CRM, Procurement software purchases and digital transformation initiatives being undertaken by Bristol Myers Squibb Ireland and its business and technology executives In addition to the reported asset values, you will also find inflation-adjusted values (third column). Pioneering paths forward in immunology > Dollars). In, Bristol-Myers Squibb. Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 16, 2022 . In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. ", Bristol-Myers Squibb, Bristol-Myers Squibb's total assets from 2015 to 2021 (in million U.S. dollars) Statista, https://www.statista.com/statistics/1100193/total-assets-of-bristol-myers-squibb/ (last visited November 10, 2022), Bristol-Myers Squibb's total assets from 2015 to 2021, World pharmaceutical sales 2017-2021 by region, World pharmaceutical market distribution by submarket 2014-2021, Revenues of top 10 global pharmaceutical markets 2020, Share of pharmaceutical value worldwide 2021, by country, Value share of pharmaceutical subsectors worldwide 2003 vs. 2021, Top therapy classes by spending global market 2026 forecast, Global pharmaceutical revenue by technology 2012-2026, Worldwide Rx drug sales excluding generics and orphan drugs 2012-2026, Projection of global revenue for orphan prescription drugs 2012-2026, Worldwide generic prescription drug sales 2012-2026, Revenue of the global OTC pharmaceutical market 2012-2025, Tota pharmaceutical value worldwide 2021, by subsector, Top 50 pharmaceutical companies - Rx sales and R&D spending 2021, Global Rx drug market share by top companies 2019 and 2026, Top 10 biotech and pharmaceutical companies based on market cap 2022, Johnson & Johnson's total sales 2005-2021, Projected top pharmaceutical companies based on new sales 2022, Global top pharmaceutical companies based on R&D spending 2026, Patent expiration risks for total worldwide prescription drug revenue 2020-2028, Worldwide prescription drug revenue - market risk from patent expiration 2020-2028, Pharmaceutical industry - number of new substances 1998-2021, Pharma companies worldwide with active R&D pipelines 2001-2022, Number of novel drugs approved annually by CDER 2008-2021, Projected most valuable R&D projects based on net present value 2021, World pharmaceutical sales by region forecast 2025, CAGR by product type in pharmaceutical markets forecast 2022-2026, Country comparison in spending on medicine 2026, Leading global pharmaceutical products by projected sales 2026, Top global biopharma drugs by lifetime sales up to 2026, COVID-19 vaccine dose numbers by top manufacturer 2021, Number of COVID-19 drugs in development worldwide by phase June 2022, BARDA funding for the development of COVID-19 vaccines in the U.S. 2021, Forecasted sales of select COVID-19 vaccines worldwide 2021-2022, Gilead Science's remdesivir manufacturing projections 2020, Global mRNA vaccines and therapeutics market for COVID-19 Q4 2020 vs. 2025, Bristol-Myers Squibb's R&D spending 2015-2021, Bristol-Myers Squibb - revenue share of key products 2006-2020, Bristol-Myers Squibb's employee number 2015-2021, Bristol-Myers Squibb's net earnings 2007-2021, Bristol-Myers Squibb's revenue by region 2010-2021, Total assets of Yunnan Baiyao Group China 2012-2021, Total assets of Celgene 2014-2018, by year, Total assets of China Resources Sanjiu 2012-2020, Medco Health Solutions' total assets 2006-2011, Astellas Pharma's total assets FY 2012-2021, Bristol-Myers Squibb's total assets from 2015 to 2021 (in million U.S. dollars), Find your information in our database containing over 20,000 reports, Find a brief overview of all Outlooks here, Tools and Tutorials explained in our Media Centre. We estimate Bristol Myers Squibb's Valuation to be around $78 per share, just 9% above the current market price of $72. This statistic shows the number of employees of pharmaceutical company Bristol-Myers Squibb from 2015 to 2020. Then you can access your favorite statistics via the star in the header. **Included as part of the new product portfolio In November, the company announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy to April 28, 2022. ***Included as part of the key loss of exclusivity (LOE) brands, FOURTH QUARTER PRODUCT AND PIPELINE UPDATE, In December, the company issued its 2021 Global Access Report that detailed Bristol Myers Squibbs efforts and progress towards advancing access to healthcare and health equity globally through its own efforts and in partnership with other stakeholders. Research and development expenses decreased 30% to $2.6 billion in the quarter. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Amortization of acquired intangible assets was $2.5 billion in the quarter primarily due to the Celgene Acquisition. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Cash & ST Investments / Total Assets. Bristol Myers Squibb total assets from 2010 to 2022. It may sound complicated, but actually it is . . Bristol-Myers Squibb Co. non-current assets decreased from 2019 to 2020 and from 2020 to 2021. Their most recent investment was on Nov 3, 2022, when Kura Oncology raised $25M. Key 2022 GAAP and non-GAAP line-item guidance assumptions are: The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. . Bristol-Myers Squibb Total Assets are fairly stable at the moment as compared to the past year. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. Bristol-Myers Squibb Co. current assets increased from 2019 to 2020 and from 2020 to 2021. Bristol Myers Squibb. The assets of the Program were commingled within the Savings Plan Master Trust with the assets of the Bristol-Myers Squibb Company Employee Incentive Thrift Plan (the Thrift Plan). View and export this data back to 1987. ***Included as part of the key loss of exclusivity (LOE) brands, *In excess of +100%. Amortization of acquired intangible assets decreased 4% to $2.4 billion in the quarter primarily due to an extended marketed product rights exclusivity period. It's used as an indicator to show how well a company. Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. Total Current Assets explanation, calculation, historical dat BMY (Bristol-Myers Squibb Co) Total Current Assets Get Your 7-Day Free Trial! Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. The company reported net loss attributable to Bristol Myers Squibb of $85 million, or $0.04 per share, in the second quarter, compared to net earnings of $1.4 billion, or $0.87 per share, for. Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. Presently, Bristol-Myers Squibb Company shares are logging -4.67% during the 52-week period from high price, and 44.36% higher than the lowest price point for the same timeframe. BMY (Bristol-Myers Squibb Co) Total Assets as of today (November 01, 2022) is $98,196 Mil. Dies geschieht in Ihren Datenschutzeinstellungen. 10-K (reporting date: 2018-12-31), Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. The study was conducted by The Bristol Myers Squibb-Janssen Collaboration. Media: media@bms.com . Forward-looking statements are based on current expectations and projections about the companys future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the companys control and could cause the companys future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Total Assets (Quarterly) Chart. (, In December, the company announced that its Board of Directors approved an increase in the quarterly dividend and authorized an additional $15 billion, multi-year share repurchase program. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Analyze Bristol-Myers Squibb Total Assets. The company's quarterly Total Assets is the company's net worth. bristol myers squibb press release. Sie knnen Ihre Einstellungen jederzeit ndern. Bristol-Myers Squibb Co. inventories decreased from 2019 to 2020 but then slightly increased from 2020 to 2021. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. At its current levels, BMY stock is trading at a P/E multiple of under. 29 min read Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of. The Bristol Myers Squibb booth stands during the 5th China International Import Expo at the National Exhibition and Convention Center on November 5, 2022 in Shanghai, China. Total $ 31,450 $ 18,200 . Director, Asset Management & Facilities, Biologics. Knowledge of Asset Management and Total cost of ownership (life cycle management) Be able to be a mature spoke person with regulatory agencies; Ability to read electrical schematics and ladder logic; . This graph helps you visualize the growth of assets year on year. To use individual functions (e.g., mark statistics as favourites, set Total Revenues $11,985 $11,068 8% Earnings (Loss) Per Share - GAAP 1.07 . Get full access to all features within our Corporate Solutions. Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. Below table contains data used to create the total assets chart. Call us: 07540 706930; Email: vipul.patel@quantum-fa.co.uk; Need Financial Advisers? These statements are likely to relate to, among other things, the companys ability to execute successfully its strategic plans, including its business development strategy and capital allocation strategy, planned product launches and updates, expectations relating to its pipeline and in relation to its ability to realize the projected benefits of the Celgene acquisition and the MyoKardia acquisition, the full extent of the impact of the COVID-19 pandemic on the companys operations and the development and commercialization of its products, potential laws and regulations to lower drug costs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about the companys ability to retain patent exclusivity of certain products, and the impact and the result of governmental investigations.